|Bid||9.12 x 900|
|Ask||9.45 x 1100|
|Day's range||8.94 - 9.55|
|52-week range||6.43 - 19.11|
|Beta (5Y monthly)||0.59|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.00|
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) One-Time Cell Dosing with Proprietary Lymphodepletion (Single Dose FCA90) Resulted in 67% Overall Response Rate (ORR) and 58% Complete Response (CR) RateResponses in Patients that Received Single Dose FCA90 Were Durable with a 50% CR Rate at Both Six and 12 Months
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...